Novartis to run COVID-19 preliminary of antimalarial drug Kumar Jeetendra | April 20, 2020 Novartis has won the thumbs up from the U.S. Nourishment and Drug Administration to direct a randomized preliminary of jungle fever medicate hydroxychloroquine against COVID-19 illness, the Swiss drugmaker said on Monday, to check whether it helps patients. The decades-old nonexclusive medication got FDA crisis use approval this month for its unapproved use for coronavirus …
Could the world have a coronavirus immunization by September? Kumar Jeetendra | April 28, 2020 A coronavirus immunization is one bit nearer because of promising outcomes following testing on monkeys – with across the board accessibility to conceivably come as ahead of schedule as September. Six rhesus macaque monkeys were infused with a portion of the Oxford University researchers’ antibody and remain contamination free a month subsequent to being presented …
FDA favors Novartis medicate for a difficult to-treat sort of lung malignancy Kumar Jeetendra | May 7, 2020 Novartis AG on Wednesday got the U.S. Nourishment and Drug Administration’s endorsement for its medication to get patients with an extreme treat type of lung malignant growth, the drugmaker said. The medication, Tabrecta, has been endorsed to treat patients with a MET exon14 skipping-changed non-little cell lung malignant growth that has spread to different pieces …
